Evidence map›Paper›PMID 23434756›Full record

ArticleNature2013

CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance.

Adam Greenbaum, Yen-Michael S Hsu, Ryan B Day, Laura G Schuettpelz, Matthew J Christopher, Joshua N Borgerding, Takashi Nagasawa, Daniel C Link

Open access · greenAbstract read
In one paragraph

Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 836 papers.

0numbers the graph read from it
0cells of the map it votes in
836citing papers in PubMed
74.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

836 citing papers in PubMed, 1,330 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

776 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Adam GreenbaumDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Yen-Michael S Hsu
Ryan B Day
Laura G Schuettpelz
Matthew J Christopher
Joshua N Borgerding
Takashi Nagasawa
Daniel C Link
Washington University in St. Louis · USJapan Science and Technology Agency · JP

Funding

ROLE OF THE G-CSF RECEPTOR IN PROGENITOR MOBILIZATIONR01HL060772 · NHLBI · WASHINGTON UNIVERSITY · PI LINK, DANIEL C · 1999 to 2014
$3.9M
The Role of N-Cadherin in the Regulation of the Hematopoietic Stem Cell NicheF30HL097423 · NHLBI · WASHINGTON UNIVERSITY · PI GREENBAUM, ADAM MICHAEL · 2009 to 2012
$139k
The effect of niche-specific cxcl12 production on B lymphopoiesis.F30HL112552 · NHLBI · WASHINGTON UNIVERSITY · PI DAY, RYAN BRENT · 2012 to 2014
$105k
NHLBI NIH HHS F30 HL097423NHLBI NIH HHS F30 HL112552NHLBI NIH HHS R01 HL060772NHLBI NIH HHS R01 HL60772
6 · The paper itself

Abstract

Haematopoietic stem cells (HSCs) primarily reside in the bone marrow where signals generated by stromal cells regulate their self-renewal, proliferation and trafficking. Endosteal osteoblasts and perivascular stromal cells including endothelial cells, CXCL12-abundant reticular cells, leptin-receptor-positive stromal cells, and nestin-green fluorescent protein (GFP)-positive mesenchymal progenitors have all been implicated in HSC maintenance. However, it is unclear whether specific haematopoietic progenitor cell (HPC) subsets reside in distinct niches defined by the surrounding stromal cells and the regulatory molecules they produce. CXCL12 (chemokine (C-X-C motif) ligand 12) regulates both HSCs and lymphoid progenitors and is expressed by all of these stromal cell populations. Here we selectively deleted Cxcl12 from candidate niche stromal cell populations and characterized the effect on HPCs. Deletion of Cxcl12 from mineralizing osteoblasts has no effect on HSCs or lymphoid progenitors. Deletion of Cxcl12 from osterix-expressing stromal cells, which include CXCL12-abundant reticular cells and osteoblasts, results in constitutive HPC mobilization and a loss of B-lymphoid progenitors, but HSC function is normal. Cxcl12 deletion from endothelial cells results in a modest loss of long-term repopulating activity. Strikingly, deletion of Cxcl12 from nestin-negative mesenchymal progenitors using Prx1-cre (Prx1 also known as Prrx1) is associated with a marked loss of HSCs, long-term repopulating activity, HSC quiescence and common lymphoid progenitors. These data suggest that osterix-expressing stromal cells comprise a distinct niche that supports B-lymphoid progenitors and retains HPCs in the bone marrow, and that expression of CXCL12 from stromal cells in the perivascular region, including endothelial cells and mesenchymal progenitors, supports HSCs.

Indexed as

AnimalsB-LymphocytesBone MarrowCell MovementChemokine CXCL2Hematopoietic Stem CellsHomeodomain ProteinsIntermediate Filament ProteinsLymphoid Progenitor CellsMesenchymal Stem CellsMiceNerve Tissue ProteinsNestinReceptor, Platelet-Derived Growth Factor alphaStem Cell NicheChemokine CXCL2Cxcl2 protein, mouseHomeodomain ProteinsIntermediate Filament ProteinsNerve Tissue ProteinsNes protein, mouseNestinPrrx1 protein, mouseReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID23434756
PMCPMC3600148
OpenAlexW2012056552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.